vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and Nutex Health, Inc. (NUTX). Click either name above to swap in a different company.
ANI PHARMACEUTICALS INC is the larger business by last-quarter revenue ($247.1M vs $151.7M, roughly 1.6× Nutex Health, Inc.). ANI PHARMACEUTICALS INC runs the higher net margin — 11.1% vs 7.8%, a 3.3% gap on every dollar of revenue. On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs -41.1%). Nutex Health, Inc. produced more free cash flow last quarter ($69.0M vs $29.1M). Over the past eight quarters, Nutex Health, Inc.'s revenue compounded faster (50.0% CAGR vs 34.1%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
Nutex Health Inc. is an American for-profit health care company and operator of healthcare facilities headquartered in Houston, Texas.
ANIP vs NUTX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $151.7M |
| Net Profit | $27.5M | $11.8M |
| Gross Margin | — | 30.4% |
| Operating Margin | 14.1% | 20.4% |
| Net Margin | 11.1% | 7.8% |
| Revenue YoY | 29.6% | -41.1% |
| Net Profit YoY | 367.5% | -80.8% |
| EPS (diluted) | $1.14 | $2.34 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $247.1M | $151.7M | ||
| Q3 25 | $227.8M | $267.8M | ||
| Q2 25 | $211.4M | $244.0M | ||
| Q1 25 | $197.1M | $211.8M | ||
| Q4 24 | $190.6M | $257.6M | ||
| Q3 24 | $148.3M | $78.8M | ||
| Q2 24 | $138.0M | $76.1M | ||
| Q1 24 | $137.4M | $67.5M |
| Q4 25 | $27.5M | $11.8M | ||
| Q3 25 | $26.6M | $55.4M | ||
| Q2 25 | $8.5M | $-17.7M | ||
| Q1 25 | $15.7M | $21.2M | ||
| Q4 24 | $-10.3M | $61.6M | ||
| Q3 24 | $-24.2M | $-8.8M | ||
| Q2 24 | $-2.3M | $-364.0K | ||
| Q1 24 | $18.2M | $-364.0K |
| Q4 25 | — | 30.4% | ||
| Q3 25 | — | 57.8% | ||
| Q2 25 | — | 51.2% | ||
| Q1 25 | — | 55.9% | ||
| Q4 24 | — | 55.0% | ||
| Q3 24 | — | 27.8% | ||
| Q2 24 | — | 29.7% | ||
| Q1 24 | — | 15.1% |
| Q4 25 | 14.1% | 20.4% | ||
| Q3 25 | 15.9% | 48.7% | ||
| Q2 25 | 6.6% | 13.8% | ||
| Q1 25 | 13.3% | 38.1% | ||
| Q4 24 | -2.3% | 44.4% | ||
| Q3 24 | -13.8% | 12.3% | ||
| Q2 24 | 3.7% | 7.0% | ||
| Q1 24 | 14.8% | 2.1% |
| Q4 25 | 11.1% | 7.8% | ||
| Q3 25 | 11.7% | 20.7% | ||
| Q2 25 | 4.0% | -7.3% | ||
| Q1 25 | 8.0% | 10.0% | ||
| Q4 24 | -5.4% | 23.9% | ||
| Q3 24 | -16.3% | -11.2% | ||
| Q2 24 | -1.7% | -0.5% | ||
| Q1 24 | 13.2% | -0.5% |
| Q4 25 | $1.14 | $2.34 | ||
| Q3 25 | $1.13 | $7.76 | ||
| Q2 25 | $0.36 | $-2.95 | ||
| Q1 25 | $0.69 | $3.33 | ||
| Q4 24 | $-0.45 | $11.56 | ||
| Q3 24 | $-1.27 | $-1.72 | ||
| Q2 24 | $-0.14 | $-0.07 | ||
| Q1 24 | $0.82 | $-0.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $185.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $540.7M | $329.4M |
| Total Assets | $1.4B | $918.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $285.6M | $185.6M | ||
| Q3 25 | $262.6M | $166.0M | ||
| Q2 25 | $217.8M | $96.7M | ||
| Q1 25 | $149.8M | $84.7M | ||
| Q4 24 | $144.9M | $40.6M | ||
| Q3 24 | $145.0M | $46.9M | ||
| Q2 24 | $240.1M | $40.8M | ||
| Q1 24 | $228.6M | $30.0M |
| Q4 25 | $540.7M | $329.4M | ||
| Q3 25 | $505.8M | $317.2M | ||
| Q2 25 | $436.8M | $235.3M | ||
| Q1 25 | $418.6M | $176.9M | ||
| Q4 24 | $403.7M | $132.4M | ||
| Q3 24 | $405.9M | $60.4M | ||
| Q2 24 | $455.8M | $62.7M | ||
| Q1 24 | $452.0M | $63.0M |
| Q4 25 | $1.4B | $918.5M | ||
| Q3 25 | $1.4B | $964.5M | ||
| Q2 25 | $1.3B | $841.0M | ||
| Q1 25 | $1.3B | $761.9M | ||
| Q4 24 | $1.3B | $655.3M | ||
| Q3 24 | $1.3B | $438.5M | ||
| Q2 24 | $920.8M | $422.4M | ||
| Q1 24 | $914.5M | $404.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | $70.4M |
| Free Cash FlowOCF − Capex | $29.1M | $69.0M |
| FCF MarginFCF / Revenue | 11.8% | 45.5% |
| Capex IntensityCapex / Revenue | 0.5% | 0.9% |
| Cash ConversionOCF / Net Profit | 1.10× | 5.95× |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | $245.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.4M | $70.4M | ||
| Q3 25 | $44.1M | $99.5M | ||
| Q2 25 | $75.8M | $27.3M | ||
| Q1 25 | $35.0M | $51.0M | ||
| Q4 24 | $15.9M | $54.0K | ||
| Q3 24 | $12.5M | $6.8M | ||
| Q2 24 | $17.4M | $13.3M | ||
| Q1 24 | $18.3M | $3.1M |
| Q4 25 | $29.1M | $69.0M | ||
| Q3 25 | $38.0M | $99.2M | ||
| Q2 25 | $71.8M | $26.5M | ||
| Q1 25 | $32.5M | $50.9M | ||
| Q4 24 | $13.5M | $-341.0K | ||
| Q3 24 | $7.7M | $6.2M | ||
| Q2 24 | $13.0M | $12.7M | ||
| Q1 24 | $13.7M | $2.3M |
| Q4 25 | 11.8% | 45.5% | ||
| Q3 25 | 16.7% | 37.0% | ||
| Q2 25 | 34.0% | 10.9% | ||
| Q1 25 | 16.5% | 24.0% | ||
| Q4 24 | 7.1% | -0.1% | ||
| Q3 24 | 5.2% | 7.8% | ||
| Q2 24 | 9.4% | 16.7% | ||
| Q1 24 | 10.0% | 3.4% |
| Q4 25 | 0.5% | 0.9% | ||
| Q3 25 | 2.7% | 0.1% | ||
| Q2 25 | 1.9% | 0.3% | ||
| Q1 25 | 1.3% | 0.0% | ||
| Q4 24 | 1.3% | 0.2% | ||
| Q3 24 | 3.2% | 0.8% | ||
| Q2 24 | 3.2% | 0.7% | ||
| Q1 24 | 3.3% | 1.1% |
| Q4 25 | 1.10× | 5.95× | ||
| Q3 25 | 1.66× | 1.80× | ||
| Q2 25 | 8.87× | — | ||
| Q1 25 | 2.23× | 2.40× | ||
| Q4 24 | — | 0.00× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 1.00× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
NUTX
| Hospital Division | $143.7M | 95% |
| Population Health Management Division | $8.0M | 5% |
